[SP5-3C-8] Efficacy and safety of rituximab in autoimmune CNS disease of Chinese children
[Background] Although some recent studies have showed effectiveness and safety of rituximab in autoimmune central nervous system (CNS) diseases, data in pediatric patients was limited.
[Objective] To evaluate rituximab efficacy and safety in pediatric autoimmune CNS disease.
[Methods] A retrospective study was conducted in children hospitalized in Peking University First Hospital from 2010.09 to 2016.08, who diagnosed with autoimmune CNS diseases and treated with rituximab. The modified Rankin Scale score (mRS),subjective assessment from clinicians and annualized relapse rate (ARR)were used to evaluate efficacy. Any side effect during rituximab usage was recorded, especially infection, infusion adverse event and side effect in hematologic system.
[Result] 42 patients were included, containing 8 types of autoimmune CNS disease. After a median 8.5 months of rituximab usage, improvement of the mRS score was a median of 1. According to subjective assessment from clinicians, a definite and probable effect was found in 37 patients (86.10%). ARR after rituximab usage was reduced in neuromyelitisoptica spectrum disorders (NMOSD) and multiple sclerosis (MS).And we found rituximab had the most remarkable efficacy in NMOSDand myasthenia gravis (MG). Infusion adverse event, infection and side effect in hematologic system were reported in 4 (9.52%), 15 (35.71%) and 9 (21.43%) patients respectively. Severe infection and infusion adverse event were rare.
[Conclusion] Rituximab is effective and safety in treatment of pediatric CNS disease. The efficacy of rituximab is different in different diseases.
[Objective] To evaluate rituximab efficacy and safety in pediatric autoimmune CNS disease.
[Methods] A retrospective study was conducted in children hospitalized in Peking University First Hospital from 2010.09 to 2016.08, who diagnosed with autoimmune CNS diseases and treated with rituximab. The modified Rankin Scale score (mRS),subjective assessment from clinicians and annualized relapse rate (ARR)were used to evaluate efficacy. Any side effect during rituximab usage was recorded, especially infection, infusion adverse event and side effect in hematologic system.
[Result] 42 patients were included, containing 8 types of autoimmune CNS disease. After a median 8.5 months of rituximab usage, improvement of the mRS score was a median of 1. According to subjective assessment from clinicians, a definite and probable effect was found in 37 patients (86.10%). ARR after rituximab usage was reduced in neuromyelitisoptica spectrum disorders (NMOSD) and multiple sclerosis (MS).And we found rituximab had the most remarkable efficacy in NMOSDand myasthenia gravis (MG). Infusion adverse event, infection and side effect in hematologic system were reported in 4 (9.52%), 15 (35.71%) and 9 (21.43%) patients respectively. Severe infection and infusion adverse event were rare.
[Conclusion] Rituximab is effective and safety in treatment of pediatric CNS disease. The efficacy of rituximab is different in different diseases.